文献速递甲状腺核医学核素与放射性配体治疗

放射性碘联合低剂量仑伐替尼治疗放射性碘敏感的高瘤负荷转移性分化型甲状腺癌:一项先导研究

Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study.
PubMed 文献 · Clin Nucl Med · 2025-09-26

该先导研究将50例放射性碘敏感的高瘤负荷转移性分化型甲状腺癌患者随机分入放射性碘联合仑伐替尼组或单纯放射性碘组,联合组客观缓解率显著更高(54.5% vs 24%,P=0.03),中位无进展生存期36个月 vs 26个月(P=0.09),但≥3级不良事件更常见(45.5% vs 8%,P=0.006)。

要点

  • 联合组客观缓解率54.5%,显著高于单纯放射性碘组的24%(P=0.03)。
  • 联合组中位无进展生存期36个月 vs 26个月,差异未达统计学显著(P=0.09)。
  • 联合组≥3级不良事件45.5%,高于单纯组8%(P=0.006),常见为高血压和手足皮肤反应。

核心结论

  • 放射性碘联合仑伐替尼提高了客观缓解率,并伴有临床上有意义的无进展生存期延长,但治疗相关毒性负担较重,强调需仔细筛选患者。

研究设计与样本

  • 先导研究, eligible患者随机分配至放射性碘联合仑伐替尼组(RAI-L组)或单纯标准放射性碘组(RAI组)。
  • 共入组50例患者,平均年龄49.1±12.6岁(范围21-67岁)。
  • 所有患者每6-9个月接受放射性碘治疗(5.5-7.4 GBq),RAI-L组额外接受仑伐替尼10 mg每日一次。
  • 主要终点为客观缓解率,次要终点包括无进展生存期、总生存期、生活质量和毒性。

主要发现

  • RAI-L组客观缓解率为54.5%,RAI组为24%,差异有统计学意义(P=0.03)。
  • 亚组分析显示联合治疗在年龄大于或等于55岁(P=0.04)、滤泡状甲状腺癌(P=0.04)、同时存在肺及肺外转移(P=0.007)和放射性碘治疗初治(P=0.02)患者中更有益。
  • RAI-L组中位无进展生存期为36个月(95% CI:24.5-47.5),RAI组为26个月(95% CI:18.9-33.1),P=0.09。
  • RAI-L组≥3级不良事件发生率为45.5%,RAI组为8%,差异有统计学意义(P=0.006)。
  • 最常见的不良事件为高血压(31.8%)和手足皮肤反应(13.6%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioactive iodine (RAI) therapy is the standard-of-care for metastatic differentiated thyroid cancer (DTC), but ~60% of patients show resistance before achieving satisfactory response. METHODS: Eligible patients were randomly assigned to RAI therapy plus lenvatinib (RAI-L arm) or standard RAI therapy alone (RAI arm). All patients were administered RAI therapy (5.5-7.4 GBq) every 6-9 months, and patients in RAI-L arm were additionally administered lenvatinib (10 mg once daily). The primary endpoint was objective response rate (ORR). Secondary endpoints included progression-free survival (PFS), overall survival, quality of life, and toxicity. RESULTS: Fifty patients were enrolled (mean age 49.1±12.6 y, range 21-67). ORR was significantly higher in the RAI-L arm compared with RAI arm (54.5% vs. 24%; P =0.03). Subgroup analysis indicated combination therapy was more beneficial in age older than or equal to 55 years ( P =0.04), follicular thyroid carcinoma ( P =0.04), presence of both pulmonary and extra-pulmonary metastases ( P =0.007), and RAI therapy-naive ( P =0.02) patients. Median PFS in the RAI-L arm was 36 months (95% CI: 24.5-47.5) versus 26 months (95% CI: 18.9-33.1) in the RAI arm ( P =0.09). Grade ≥3 adverse events were more frequent in the RAI-L arm (45.5%) compared with RAI arm (8%, P =0.006), with hypertension (31.8%) and hand-foot skin reaction (13.6%) being the most common. CONCLUSIONS: Combining RAI therapy with lenvatinib improved ORR with clinically meaningful prolongation of PFS; however, it comes with a burden of treatment-related toxicity, underscoring the need for careful patient selection.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Singareddy CTR, Bal C, Satapathy S, et al. Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study. Clin Nucl Med. 2025. PMID: 41021893. doi:10.1097/RLU.0000000000006146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。